The use of dynamic positron emission tomography imaging for evaluating the carcinogenic progression of intestinal metaplasia to esophageal adenocarcinoma

Cancer Investigation

Volumn 26, Issue 3, 2008, Pages 278-285

  Li, Yan ^a   Woodall, Charles ^a   Wo, John M ^a   Zheng, Huaiyu ^a   Ng, Chin K ^a   Ray, Mukunda B ^a   Martin, Robert C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Barrett's esophagus; Carcinogenic progression; PET imaging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; INTESTINE METAPLASIA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; REFLUX ESOPHAGITIS;

ADENOCARCINOMA; ANIMALS; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; IMMUNOHISTOCHEMISTRY; METAPLASIA; POSITRON-EMISSION TOMOGRAPHY; PRECANCEROUS CONDITIONS; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 40149094789     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701708401     Document Type: Article

References (36)

1. Blot, W.J.; Devesa, S.S.; Kneller, R.W.; Fraumeni, J.F. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. Jama-Journal of the American Medical Association 1991, 265(10), 1287-1289.
2. Pera, M.; Cameron, A.J.; Trastek, V.F.; Carpenter, H.A.; Zinsmeister, A.R. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993, 104(2), 510-513.
3. Farrow, D.C.; Vaughan, T.L. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes & Control 1996, 7(3), 322-327.
4. Pera, M.; Manterola, C.; Vidal, O.; Grande, L. Epidemiology of esophageal adenocarcinoma. J. Surg. Oncol. 2005, 92(3), 151-159.
5. Tew, W.P.; Kelsen, D.P.; Ilson, D.H. Targeted therapies for esophageal cancer. Oncologist 2005, 10(8), 590-601.
6. Enzinger, P.C.; Mayer, R.J. Esophageal cancer. N. Engl. J. Med. 2003, 349(23), 2241-2252.
7. Bailey, T.; Biddlestone, L.; Shepherd, N.; Barr, H.; Warner, P.; Jankowski, J. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence - Correlation with disease progression and dedifferentiation. American Journal of Pathology 1998, 152(1), 135-144.
8. Altorki, N.K.; Oliveria, S.; Schrump, D.S. Epidemiology and molecular biology of Barrett's adenocarcinoma. Seminars in Surgical Oncology 1997, 13(4), 270-280.
9. Cameron, A.J. Barrett's esophagus: Does the incidence of adenocarcinoma matter? American Journal of Gastroenterology 1997, 92(2), 193-194.
10. Isolauri, J.; Luostarinen, M.; Isolauri, E.; Reinikainen, P.; Viljakka, M.; Keyrilainen, O. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. American Journal of Gastroenterology 1997, 92(1), 37-41.
11. Katzka, D.A. Barrett's esophagus: surveillance and treatment. Gastroenterology Clinics of North America 2002, 31(2), 481-497.
12. Kubota, R.; Yamada, S.; Kubota, K.; Ishiwata, K.; Tamahashi, N.; Ido, T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J. Nucl. Med. 1992, 33(11), 1972-1980.
13. Spaepen, K.; Stroobants, S.; Dupont, P.; Bormans, G.; Balzarini, J.; Verhoef, G. et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur. J. Nucl. Med. Mol. Imaging. 2003, 30(5), 682-688.
14. Bhargava, P.; Reich, P.; Alavi, A.; Zhuang, H. Radiation-induced esophagitis on FDG PET imaging. Clin. Nucl. Med. 2003, 28(10), 849-850.
15. Bakheet, S.M.; Amin, T.; Alia, A.G.; Kuzo, R.; Powe, J. F-18 FDG uptake in benign esophageal disease. Clin. Nucl. Med. 1999, 24(12), 995-997.
16. Kamel, E.M..; Thumshirn, M.; Truninger, K.; Schiesser, M.; Fried, M.; Padberg, B. et al. Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J. Nucl. Med. 2004, 45(11), 1804-1810.
17. Flamen, P.; Lerut, A.; Van Cutsem, E.; Cambier, J.P.; Maes, A.; De Wever, W. et al. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J. Thorac. Cardiovasc. Surg. 2000, 120(6), 1085-1092.
18. Block, M.I.; Patterson, G.A.; Sundaresan, R.S.; Bailey, M.S.; Flanagan, F.L.; Dehdashti, F. et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac. Surg. 1997, 64(3), 770-776.
19. Flanagan, F.L.; Dehdashti, F.; Siegel, B.A.; Trask, D.D.; Sundaresan, S.R.; Patterson, G.A. et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am. J. Roentgenol. 1997, 168(2), 417-424.
20. Fukunaga, T.; Okazumi, S.; Koide, Y.; Isono, K.; Imazeki, K. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J. Nucl. Med. 1998, 39(6), 1002-1007.
21. Chen, X.X.; Ding, Y.W.; Yang, G.Y.; Bondoc, F.; Lee, M.J.; Yang, C.S. Oxidative damage in an esophageal adenocarcinoma model with rats. Carcinogenesis 2000, 21(2), 257-263.
22. Buttar, N.S.; Wang, K.K.; Leontovich, O.; Westcott, J.Y.; Pacifico, R.J.; Anderson, M.A. et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002, 122(4), 1101-1112.
23. Goldstein, S.R.; Yang, G.Y.; Curtis, S.K.; Reuhl, K.R.; Liu, B.C.; Mirvish, S.S. et al. Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. Carcinogenesis 1997, 18(11), 2265-2270.
24. Ismail-Beigi, F.; Horton, P.F.; Pope, C.E. Histological consequences of gastroesophageal reflux in man. Gastroenterology 1970, 58(2), 163-174.
25. Hetzel, D.J.; Dent, J.; Reed, W.D.; Narielvala, F.M.; Mackinnon, M.; Mccarthy, J.H. et al. Healing and Relapse of Severe Peptic Esophagitis After Treatment with Omeprazole. Gastroenterology 1988, 95(4), 903-912.
26. Daley, J.M.; Shearer, J.D.; Mastrofrancesco, B.; Caldwell, M.D. Glucose metabolism in injured tissue: a longitudinal study. Surgery 1990, 107(2), 187-192.
27. Tischler, M.E.; Fagan, J.M. Response to trauma of protein, amino acid, and carbohydrate metabolism in injured and uninjured rat skeletal muscles. Metabolism 1983, 32(9), 853-868.
28. Nelson, K.M.; Turinsky, J. Effect of insulin on glucose and amino acid uptake by skeletal muscle following burn injury. Studies with 2-deoxyglucose and alpha-aminoisobutyric acid. JPEN J. Parenter Enteral. Nutr. 1982, 6(1), 3-8.
29. Nelson, K.M.; Turinsky, J. Local effect of burn on skeletal muscle insulin responsiveness. J. Surg. Res. 1981, 31(4), 288-297.
30. Shearer, J.D.; Amaral, J.F.; Caldwell, M.D. Glucose metabolism of injured skeletalmuscle: the contribution of inflammatory cells. Circ. Shock 1988, 25(3), 131-138.
31. Weisdorf, D.J.; Craddock, P.R.; Jacob, H.S. Glycogenolysis versus glucose transport in human granulocytes: differential activation in phagocytosis and chemotaxis. Blood 1982, 60(4), 888-893.
32. Jankowski, J. Gene-Expression in Barretts Mucosa - Acute and Chronic Adaptive Responses in the Esophagus. Gut 1993, 34(12), 1649-1650.
33. Prach, A.T.; MacDonald, T.A.; Hopwood, D.A.; Johnston, D.A. Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet 1997, 350(9082), 933.
34. Yamada, S.; Kubota, K.; Kubota, R.; Ido, T.; Tamahashi, N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J. Nucl. Med. 1995, 36(7), 1301-1306.
35. Kubota, R.; Yamada, S.; Kubota, K.; Ishiwata, K.; Tamahashi, N.; Ido, T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J. Nucl. Med. 1992, 33(11), 1972-1980.
36. Reinhardt, M.J.; Kubota, K.; Yamada, S.; Iwata, R.; Yaegashi, H. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. J. Nucl. Med. 1997, 38(2), 280-287.